Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes mellitus * Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic drug) mono-therapy * HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.5-9.5% (both inclusive) * Body mass index (BMI) between 27-40 kg/m\^2 (both inclusive) * Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight) * Euthyroid subjects * Subjects should be unrestrained eaters Exclusion Criteria: * Recurrent severe hypoglycaemia * Impaired liver function * Impaired renal function * Cardiac problems * Uncontrolled treated/untreated hypertension * Known or suspected allergy to trial products or related products * Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight * Active hepatitis B and/or active hepatitis C * Positive HIV (human immunodeficiency virus) antibodies * Known or suspected abuse of alcohol or narcotics * Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator